These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
786 related articles for article (PubMed ID: 14533437)
1. Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas. Araneo M; Bruckner HW; Grossbard ML; Frager D; Homel P; Marino J; DeGregorio P; Mortazabi F; Firoozi K; Jindal K; Kozuch P Cancer Invest; 2003; 21(4):489-96. PubMed ID: 14533437 [TBL] [Abstract][Full Text] [Related]
2. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. Kozuch P; Grossbard ML; Barzdins A; Araneo M; Robin A; Frager D; Homel P; Marino J; DeGregorio P; Bruckner HW Oncologist; 2001; 6(6):488-95. PubMed ID: 11743211 [TBL] [Abstract][Full Text] [Related]
3. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer. Goel A; Grossbard ML; Malamud S; Homel P; Dietrich M; Rodriguez T; Mirzoyev T; Kozuch P Anticancer Drugs; 2007 Mar; 18(3):263-71. PubMed ID: 17264757 [TBL] [Abstract][Full Text] [Related]
4. Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors. Rachamalla R; Malamud S; Grossbard ML; Mathew S; Dietrich M; Kozuch P Anticancer Drugs; 2004 Mar; 15(3):211-7. PubMed ID: 15014353 [TBL] [Abstract][Full Text] [Related]
5. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study. Tsavaris N; Kosmas C; Skopelitis H; Gouveris P; Kopterides P; Loukeris D; Sigala F; Zorbala-Sypsa A; Felekouras E; Papalambros E Invest New Drugs; 2005 Aug; 23(4):369-75. PubMed ID: 16012797 [TBL] [Abstract][Full Text] [Related]
6. A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers. Davis EJ; Griffith KA; Kim EJ; Ruch JM; McDonnell KJ; Zalupski MM Am J Clin Oncol; 2018 Feb; 41(2):128-132. PubMed ID: 26535993 [TBL] [Abstract][Full Text] [Related]
7. Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM). Louvet C; André T; Hammel P; Selle F; Landi B; Cattan S; Fonck M; Flesch M; Colin P; Balosso J; Ruszniewski P; de Gramont A Ann Oncol; 2001 May; 12(5):675-9. PubMed ID: 11432627 [TBL] [Abstract][Full Text] [Related]
8. FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. Neuzillet C; Hentic O; Rousseau B; Rebours V; Bengrine-Lefèvre L; Bonnetain F; Lévy P; Raymond E; Ruszniewski P; Louvet C; Hammel P World J Gastroenterol; 2012 Sep; 18(33):4533-41. PubMed ID: 22969226 [TBL] [Abstract][Full Text] [Related]
9. 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. Assaf E; Verlinde-Carvalho M; Delbaldo C; Grenier J; Sellam Z; Pouessel D; Bouaita L; Baumgaertner I; Sobhani I; Tayar C; Paul M; Culine S Oncology; 2011; 80(5-6):301-6. PubMed ID: 21778770 [TBL] [Abstract][Full Text] [Related]
10. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial. Bachet JB; Hammel P; Desramé J; Meurisse A; Chibaudel B; André T; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Meyer VG; Taieb J; Volet J; Monier A; Bonnetain F; Louvet C Lancet Gastroenterol Hepatol; 2017 May; 2(5):337-346. PubMed ID: 28397697 [TBL] [Abstract][Full Text] [Related]
11. Phase II trial of 5-fluorouracil/leucovorin/gemcitabine/cisplatin as second-line treatment in patients with metastatic or recurrent colorectal carcinoma: a cancer therapeutics research group study. Chang AY; Lopes G; Hsin KW; Lim R; Fong FK; Wong J Clin Colorectal Cancer; 2007 Sep; 6(9):646-51. PubMed ID: 17945037 [TBL] [Abstract][Full Text] [Related]
12. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study. Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161 [TBL] [Abstract][Full Text] [Related]
13. Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas. Olszewski AJ; Grossbard ML; Chung MS; Chalasani SB; Malamud S; Mirzoyev T; Kozuch PS J Gastrointest Cancer; 2013 Jun; 44(2):182-9. PubMed ID: 23208490 [TBL] [Abstract][Full Text] [Related]
14. Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer. El-Rayes BF; Zalupski MM; Shields AF; Vaishampayan U; Heilbrun LK; Jain V; Adsay V; Day J; Philip PA J Clin Oncol; 2003 Aug; 21(15):2920-5. PubMed ID: 12885810 [TBL] [Abstract][Full Text] [Related]
15. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy. Reni M; Cereda S; Mazza E; Passoni P; Nicoletti R; Balzano G; Zerbi A; Arcidiacono PG; Staudacher C; Di Carlo V Am J Clin Oncol; 2008 Apr; 31(2):145-50. PubMed ID: 18391598 [TBL] [Abstract][Full Text] [Related]
16. The value of oxaliplatin in combination with continuous infusion +/- bolus 5-fluorouracil and levo-folinic acid in metastatic colorectal cancer progressing after 5FU-based chemotherapy: a GISCAD (Italian Group for the Study of Digestive Tract) cancer phase II trial. Mosconi S; Cascinu S; Zaniboni A; Catalano V; Giordani P; Beretta GD; Martignoni G; Pancera G; Baldelli AM; Poletti P; Curti C; Labianca R Tumori; 2000; 86(6):465-9. PubMed ID: 11218187 [TBL] [Abstract][Full Text] [Related]
17. Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer. Ch'ang HJ; Wang CC; Cheng AL; Hsu C; Lu YS; Chang MC; Lin JT; Wang HP; Shiah HS; Liu TW; Chang JY; Whang-Peng J; Chen LT J Gastroenterol Hepatol; 2006 May; 21(5):874-9. PubMed ID: 16704539 [TBL] [Abstract][Full Text] [Related]
18. Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer. Kim ST; Kang WK; Kang JH; Park KW; Lee J; Lee SH; Park JO; Kim K; Kim WS; Jung CW; Park YS; Im YH; Park K Br J Cancer; 2005 May; 92(10):1850-4. PubMed ID: 15870718 [TBL] [Abstract][Full Text] [Related]
19. Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM). Trouilloud I; Dupont-Gossard AC; Malka D; Artru P; Gauthier M; Lecomte T; Aparicio T; Thirot-Bidault A; Lobry C; Asnacios A; Manet-Lacombe S; Fein F; Dubreuil O; Landi B; Zaanan A; Bonnetain F; Taïeb J Eur J Cancer; 2014 Dec; 50(18):3116-24. PubMed ID: 25454414 [TBL] [Abstract][Full Text] [Related]
20. Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience. Bupathi M; Ahn DH; Wu C; Ciombor KK; Stephens JA; Reardon J; Goldstein DA; Bekaii-Saab T Med Oncol; 2016 Apr; 33(4):37. PubMed ID: 26995224 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]